In summary, our study not only expands our knowledge of the regulatory mechanisms for a medically important alternative splicing event, but also reveals a few ASOs as potential adjuvant drugs to overcome TKI resistance in CML and other tyrosine kinase-driven cancers, as well as personalized therapeutics for patients with the BIM deletion polymorphism. Here, BCL2L11 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.